Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial.
Fiche publication
Date publication
septembre 2021
Journal
Clinical genitourinary cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe, Dr EYMARD Jean-Christophe, Dr GEOFFROIS Lionnel
Tous les auteurs :
Culine S, Harter V, Gravis G, Fléchon A, Chevreau C, Mahammedi H, Laguerre B, Guillot A, Joly F, Abadie-Lacourtoisie S, Geoffrois L, Fiore FD, Roubaud G, Barthélémy P, Voog E, Emambux S, Serrate C, Saldana C, Nguyen-Tan-Hon T, Loriot Y, Eymard JC, Huillard O, Rolland F, Houédé N, Spano JP, Demery ME, Vieillot S, L'Haridon T, Hilgers W, Allory Y, Pfister C,
Lien Pubmed
Résumé
Cisplatin-based combination chemotherapy before surgery is the standard of care for muscle-invasive bladder cancer. However, the optimal chemotherapy modalities have not been precisely defined to date.
Mots clés
Cisplatin-based chemotherapy, Neoadjuvant treatment, Pathological complete response, Pathological downstaging, Perioperative chemotherapy
Référence
Clin Genitourin Cancer. 2021 Sep 8;: